Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases

Hochmair, Maximilian; Holzer, Sophia; Burghuber, Otto C.

doi: 10.1097/CAD.0000000000000410
CASE REPORTS
Buy

In patients with non-small-cell lung cancer, the presence of brain metastases requires specific treatment due to the unfavourable overall impact of these lesions. Treatment with the tyrosine kinase inhibitor afatinib was shown to induce complete and long-lasting remissions in the five patients described here. All of them had multiple brain lesions and presented with symptoms. Study evidence suggests beneficial effects of afatinib in this respect, underlining these clinical observations. Afatinib might be incorporated into current treatment algorithms, allowing for the omission of radiotherapy, provided that larger phase III trials confirm the potential of epidermal growth factor receptor tyrosine kinase inhibitors in this respect.

Respiratory Oncology Unit, Department of Respiratory and Critical Care Medicine, Otto-Wagner-Spital, Vienna, Austria

Correspondence to Maximilian Hochmair, MD, Respiratory Oncology Unit, Department of Respiratory and Critical Care Medicine, Otto-Wagner-Spital, Sanatoriumstrasse 2, Vienna 1140, Austria Tel: +43 1 910 6041240; fax: +43 1 910 6041823;e-mail: maximilian.hochmair@wienkav.at

Received May 15, 2016

Accepted June 25, 2016

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.